Do not leave for tomorrow what you can do today

Quinn, Charles T.

doi:10.1002/pbc.25669

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Thus, a high risk of death is associated with the time during and shortly after the transition to adult medical programs. 5 The reasons that cause this surge in mortality after transition are not well known. Initially they were thought to be due to difficulties in identifying adult sickle cell providers or adult hematologists to enroll transitioned patients in their programs for regular follow-up and management.…”

mentioning

confidence: 99%

“…All SCD patients and control subjects underwent blood sampling for genotype determination and biological assessment-blood cell count, hemoglobin electrophoresis, and red blood cell (RBC) density, assessed by measuring the percentage of dense RBCs (density >1.120) and the median density of RBCs. The telomere length was measured in white blood cells by using quantitative PCR 5. The telomere repeat copy number to single-gene copy number (T/S) ratio was determined with a 7900HT thermocycler (Applied Biosystems, Foster City, CA) in a 384-well format, using the comparative Ct method (T/S 5 2 -DDCt ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Beyond the transition of adolescents and young adults with sickle cell disease to adult care: Role of geography

2017

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

Beyond the transition of adolescents and young adults with sickle cell disease to adult care: Role of geography

2017

View full text Add to dashboard Cite

New Therapeutic Frontiers in Sickle Cell Disease

Quinn

2016

The Hematologist

View full text Add to dashboard Cite

Sickle Cell Disease: Populations and Policies, A Systematic Review

Pakhale,

Joseph,

Alhabeeb

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Sickle cell disease (SCD) affects over 30 million people and is most prevalent in sub-Saharan Africa, India, the Arabian Peninsula, the Caribbean, and North/South America. Globally, people with SCD disproportionately suffer premature deaths, hospitalizations due to acute complications, and significant multi-organ complications. Despite vivid similarities with Cystic Fibrosis (CF), clinical care and research is disproportionately minimal for SCD. Both CF and SCD are inherited, life-limiting, multi-system diseases; however, one mainly affects white people and the other Black people. Objective We aim to describe socio-demographics of SCD populations globally and highlight policy limitations and urgently needed changes to achieve equitable and just SCD care and research. Methods An electronic database search of Ovid MEDLINE (“sickle cell disease and marginalized people” and “policy in sickle cell disease”) was conducted for the period 1947 to May 2022. Additional information was obtained through Google Scholar, gray literature, and back references of relevant articles. Study selection and quality assessment was conducted independently in duplicate. Results Data were extracted from 137 articles, reports, and gray literature. We propose five main actionable items: 1) establish and strengthen national and international screening programs; 2) implement prevention and education programs; 3) enhance collaboration between stakeholders; 4) increase funding for SCD related research; and 5) promote new models for multidisciplinary care. Conclusions Globally, social, economic, geographical, and political factors affect access to comprehensive SCD management. Urgent policy changes are needed for equitable, inclusive, and just SCD care and research.

show abstract

Do not leave for tomorrow what you can do today

Cited by 4 publications

References 12 publications

Beyond the transition of adolescents and young adults with sickle cell disease to adult care: Role of geography

Beyond the transition of adolescents and young adults with sickle cell disease to adult care: Role of geography

New Therapeutic Frontiers in Sickle Cell Disease

Sickle Cell Disease: Populations and Policies, A Systematic Review

Contact Info

Product

Resources

About